interferon
ifn
gener
consid
antivir
cytokin
yet
newli
discov
link
failur
clear
hepat
c
viru
hcv
infect
either
spontan
respons
treatment
gener
individu
carri
allel
strongest
known
host
factor
predict
clearanc
hcv
ancestr
allel
major
variant
african
minor
variant
asian
suggest
strong
neg
genet
select
allelemost
like
driven
infecti
agent
hcv
close
resembl
protein
share
aminoacid
ident
contrast
weakli
secret
nevertheless
signal
ifnl
receptor
complex
induc
express
ifnstimul
gene
via
janu
kinasesign
transduc
activ
transcript
signal
pathway
although
variant
strongli
associ
failur
clear
hcv
infect
hcvinfect
patient
carri
allel
lower
baselin
hcv
rna
level
absenc
treatment
resolv
paradox
function
appear
induc
antivir
activ
yet
impair
effect
clearanc
hcv
may
yield
critic
new
insight
immunolog
respons
hcv
infect
ifn
biolog
nterferon
ifn
character
larg
part
abil
induc
antivir
activ
target
cell
express
match
cognat
receptor
complex
fact
name
cytokin
famili
refer
abil
interfer
viral
replic
within
host
cell
recent
discov
protein
classifi
ifn
gene
symbol
name
assign
human
genom
organ
gene
hugo
nomenclatur
committe
conjunct
nomenclatur
committe
intern
cytokin
interferon
societi
basi
sequenc
similar
ifnl
protein
well
evid
induc
antivir
respons
activ
janu
kinas
jak
signal
transduc
activ
transcript
stat
pathway
express
interferonstimul
gene
isg
discov
gene
protein
genet
genom
studi
hepat
c
viru
hcv
infect
demonstr
strong
associ
genet
variant
creat
failur
clear
hcv
infect
either
spontan
respons
treatment
pegyl
ifna
ribavirin
prokuninaolsson
other
appear
therefor
impair
hcv
clearanc
asyetundefin
mechan
summar
current
knowledg
discuss
question
address
resolv
paradox
biolog
activ
first
member
ifnl
famili
discov
simultan
comput
predict
base
genom
sequenc
independ
research
group
use
differ
nomenclatur
report
discoveri
protein
kotenko
other
sheppard
other
late
conjunct
grant
offici
name
gene
symbol
hugo
nomenclatur
committe
chang
offici
symbol
gene
respect
chang
consist
widespread
recognit
cytokin
function
primarili
ifn
interleukin
protein
encod
gene
highli
similar
aminoacid
ident
gene
also
almost
ident
noncod
sequenc
includ
upstream
downstream
flank
region
kotenko
other
sheppard
other
fox
other
ident
kotenko
other
sheppard
other
classifi
typeiii
ifn
signal
receptor
complex
distinct
receptor
use
type
type
ii
ifn
de
weerd
nguyen
viral
infect
induc
express
type
iii
ifn
varieti
cell
type
kotenko
other
sheppard
other
cytokin
signal
heterodimer
receptor
complex
consist
ligandbind
chain
accessori
chain
kotenko
other
sheppard
other
donnelli
kotenko
ifn
induc
antivir
activ
cell
express
correspond
cell
surfac
receptor
express
larg
restrict
cell
epitheli
origin
sommereyn
other
mordstein
other
cell
type
includ
epiderm
bronchial
gastrointestin
epitheli
cell
well
hepatocyt
contrast
type
leukocyt
express
ifnl
receptor
therefor
respons
ifnl
diegelmann
other
dickensheet
other
consequ
type
iii
ifn
limit
function
rang
type
ifn
ifnab
whose
receptor
wide
express
somat
cell
type
thu
type
iii
ifn
may
evolv
specif
render
protect
epithelium
bind
type
iii
ifn
lead
rapid
conform
chang
facilit
recruit
complex
gad
other
mikni
other
ternari
complex
consist
type
iii
ifn
assembl
receptorassoci
tyrosin
kinas
activ
mediat
tyrosin
phosphoryl
intracellular
domain
chain
result
format
phosphotyrosinecontain
peptid
motif
provid
dock
site
stat
protein
type
iii
ifn
signal
result
format
ifnstimul
gene
factor
transcript
factor
complex
consist
assembl
transloc
cytosol
nucleu
bind
interferonstimul
respons
element
isr
promot
numer
isg
protein
encod
isg
mediat
varieti
antivir
antiprolif
activ
gene
induc
type
iii
ifn
appear
essenti
induc
ifna
doyl
other
marcello
other
downstream
biolog
activ
induc
either
group
appear
similar
addit
abil
activ
jakstat
signal
pathway
ifnlambda
subtyp
ie
also
induc
activ
signal
pathway
includ
mitogenactiv
protein
map
kinas
cjun
ntermin
kinas
jnk
certain
cell
type
zhou
other
addit
report
signal
canon
receptor
complex
result
activ
ribosom
protein
kinas
downstream
effector
eukaryot
initi
factor
sever
tumor
cell
line
includ
human
colon
carcinoma
human
retin
epitheli
cell
line
kroczynska
other
although
type
type
iii
ifn
signal
distinct
receptor
primari
intracellular
signal
pathway
activ
type
type
iii
ifn
common
howev
number
import
differ
antivir
activ
induc
type
versu
type
iii
ifn
first
mention
earlier
type
ifn
receptor
broadli
express
virtual
somat
cell
includ
type
leukocyt
contrast
type
iii
ifn
receptor
predominantli
express
nonhematolog
cell
type
especi
cell
epitheli
origin
bronchial
epithelium
gastrointestin
epithelium
keratinocyt
second
viral
infect
studi
sever
mous
model
shown
type
iii
ifn
play
promin
role
type
ifn
mediat
antivir
protect
certain
type
virus
preferenti
infect
gastrointestin
andor
respiratori
epithelium
exampl
pott
cowork
found
ifnlambda
receptor
gene
knockout
mice
markedli
impair
abil
control
infecti
challeng
live
rotaviru
wherea
mice
lack
type
ifn
receptor
ie
knockout
respond
similarli
wildtyp
mice
furthermor
treatment
typeiii
ifn
ifnl
typei
ifn
ifna
protect
wildtyp
mice
rotaviru
infect
find
indic
type
iii
ifn
type
ifn
play
domin
role
host
defens
certain
type
viral
infect
also
increas
evid
base
infecti
challeng
studi
mice
type
iii
ifn
function
along
type
ifn
mediat
protect
infect
respiratori
virus
influenza
viru
respiratori
syncyti
viru
preferenti
infect
airway
epitheli
cell
jewel
other
mordstein
other
earli
clinic
trial
recombin
treatment
chronic
hepat
c
indic
antivir
effect
similar
recombin
ifna
yet
induc
fewer
advers
effect
due
limit
rang
cell
express
muir
other
discoveri
facilit
genomewid
associ
studi
gwa
hcv
infect
gwa
result
report
independ
group
identifi
number
singl
nucleotid
polymorph
snp
marker
locat
upstream
formerli
chromosom
region
associ
respons
treatment
pegyl
ifna
ribavirin
among
patient
chronic
hepat
c
ge
other
suppiah
other
tanaka
other
snp
strong
linkag
disequilibrium
ld
genotyp
base
snp
highli
correl
result
provid
similar
genet
associ
subsequ
report
confirm
find
show
snp
marker
also
associ
likelihood
spontan
hcv
clearanc
thoma
other
rauch
other
specif
genotyp
snp
locat
kb
upstream
report
host
factor
strongli
associ
respons
pegyl
ifna
ribavirin
treatment
hcvinfect
patient
thompson
other
individu
carri
allel
ie
ct
tt
genotyp
less
like
respond
treatment
copi
allel
furthermor
allel
found
common
african
european
asian
thoma
other
explain
part
previou
observ
african
american
less
like
respond
treatment
hepat
c
basi
find
genet
test
introduc
help
predict
likelihood
treatment
respons
hcv
infect
fda
recommend
genotyp
routin
assess
clinic
trial
new
agent
treatment
chronic
hepat
c
pacanowski
other
addit
associ
improv
viral
clearanc
seemingli
inconsist
phenotyp
also
link
genotyp
notabl
allel
associ
poorer
treatment
respons
also
associ
lower
pretreat
hcv
rna
level
ge
other
wellestablish
predictor
treatment
success
addit
well
strongli
link
allel
shown
associ
higher
intrahepat
express
isg
treatment
honda
other
urban
other
thu
rang
phenotyp
associ
allel
paradox
encompass
decreas
treatmentinduc
viral
clearanc
face
higher
isg
express
level
lower
hcv
rna
level
treatment
snp
near
strong
ld
potenti
function
number
hypothes
propos
explain
genet
variat
within
near
might
impair
hcv
clearanc
review
horner
gale
two
earlier
studi
mrna
express
lymphocyt
suggest
express
level
greater
individu
genotyp
favor
treatment
respons
suppiah
other
tanaka
other
anoth
studi
observ
similar
effect
ge
other
studi
express
liver
also
yield
inconsist
result
fukuhara
other
report
intrahepat
express
ie
combin
mrna
significantli
lower
individu
carri
unfavor
hcv
clearanc
allel
howev
studi
found
associ
intrahepat
express
genotyp
either
honda
other
urban
other
snp
report
gwa
nonsynonym
code
variant
strong
ld
appear
alter
potenc
function
urban
other
recent
mcfarland
other
suggest
polymorph
lie
untransl
region
strong
ld
function
variant
affect
stabil
transcript
influenc
adenosineuridinerich
elementmedi
decay
mrna
bind
hcvinduc
microrna
infect
earlier
studi
patient
european
ancestri
treat
pegyl
ifna
ribavirin
associ
treatment
respons
compar
genotyp
de
castellarnau
other
would
expect
base
high
ld
polymorph
previou
analysi
spontan
clearanc
hcv
egyptian
popul
report
genotyp
provid
somewhat
weaker
overal
associ
genotyp
gwa
marker
pedergnana
other
thu
attempt
identifi
function
genet
variant
within
function
mechan
link
fail
yield
consist
result
broadli
function
studi
aim
specif
beg
question
variat
singl
member
close
relat
type
iii
ifn
group
could
account
appar
contradictori
phenotyp
observ
gene
discov
sequenc
rna
sampl
deriv
primari
human
hepatocyt
phh
treat
polyinosin
polycytidyl
acid
poli
c
synthet
doublestrand
rna
mimic
hcv
infect
earli
report
discoveri
previous
unrecogn
transient
induc
region
upstream
prove
contain
novel
gene
among
sever
transcript
fig
prokuninaolsson
other
furthermor
show
control
herit
germlin
dinucleotid
frameshift
variant
denot
origin
design
locat
exon
fig
allel
creat
open
read
frame
fulllength
protein
wherea
altern
allel
locu
creat
prokuninaolsson
other
thu
function
variant
control
gener
variant
still
commonli
refer
actual
locat
within
intron
fig
prokuninaolsson
other
therefor
properli
call
ld
creat
unfavor
allel
high
asian
r
european
r
prokuninaolsson
other
mean
racial
group
almost
alway
inherit
togeth
highli
link
variant
difficult
imposs
determin
variant
strongli
associ
outcom
therefor
like
causal
howev
found
among
african
ld
weaker
popul
r
enabl
us
demonstr
hcv
rna
declin
day
treatment
pegyl
ifna
ribavirin
strongli
associ
genotyp
among
african
american
patient
enrol
virahep
studi
fig
prokuninaolsson
other
among
patient
also
strongli
associ
measur
treatment
respons
includ
sustain
virolog
respons
svr
although
differ
reach
statist
signific
found
consist
result
genotyp
associ
spontan
hcv
clearanc
african
american
prokuninaolsson
other
aka
other
among
patient
european
ancestri
found
due
strong
ld
genotyp
yield
similar
ident
result
prokuninaolsson
other
howev
sinc
other
report
respons
treatment
pegyl
ifna
ribavirin
strongli
associ
genotyp
among
european
bibert
other
franco
other
number
host
factor
shown
predict
respons
treatment
chronic
hepat
c
previous
thompson
colleagu
show
among
factor
genotyp
strongest
factor
respons
treatment
pegyl
ifna
ribavirin
thompson
other
extrapol
new
data
suggest
genotyp
may
singl
strongest
host
factor
predict
treatment
respons
close
resembl
protein
share
aminoacid
ident
similar
within
first
last
f
helic
sequenc
correspond
region
type
iii
ifn
interact
chain
primari
receptor
distinct
helix
predict
bind
region
chain
second
chain
ifnl
receptor
complex
prokuninaolsson
other
despit
sequenc
dissimilar
base
structur
model
studi
ham
other
conclud
overal
structur
similar
independ
work
group
indic
signal
ifnl
receptor
complex
ham
other
gener
biolog
activ
recombin
escherichia
coli
express
system
use
cell
express
chain
well
poorli
meager
other
fig
median
decreas
hepat
c
viru
hcv
rna
iuml
african
american
particip
virahepc
studi
first
day
treatment
pegyl
ifna
ribavirin
p
comparison
mean
differ
hcv
rna
level
day
genotyp
group
ie
respect
group
prokuninaolsson
other
permiss
natur
publish
investig
demonstr
ectop
express
chain
cell
reconstitut
respons
ham
other
fig
also
show
knockdown
endogen
express
use
silenc
rna
sirna
markedli
diminish
respons
cell
ham
other
experi
show
signal
receptor
complex
receptor
requir
signal
author
also
suggest
addit
protein
residu
respons
bind
receptor
residu
nonconserv
new
independ
work
prokuninaolsson
laboratori
show
similar
result
cell
transient
transfect
express
construct
either
silenc
sirna
block
antibodi
inhibit
signal
muchmor
other
induc
express
isg
via
jakstat
signal
pathway
exert
antivir
effect
transfect
experi
demonstr
induc
phosphoryl
activ
isreluc
report
gene
induc
express
multipl
isg
gener
antivir
respons
hcv
prokuninaolsson
other
use
recombin
protein
ham
other
confirm
induc
express
isg
furthermor
despit
structur
differ
note
earlier
investig
also
show
level
isg
induct
antivir
activ
similar
ham
other
antivir
potenc
found
quit
similar
test
differ
hepat
cell
line
also
exhibit
compar
potenc
assay
abil
induc
antivir
activ
differ
human
coronavirus
merscov
cultur
primari
human
bronchial
epitheli
cell
antivir
activ
correl
equival
induct
level
sever
isg
includ
oasl
similar
antivir
activ
observ
also
noteworthi
shown
potent
dellgren
other
vitro
result
appear
consist
observ
studi
among
individu
chronic
hepat
c
note
unfavor
host
genotyp
associ
higher
express
isg
lower
hcv
rna
level
sever
recent
studi
explor
hepat
express
due
locat
defin
polymorph
first
exon
splice
composit
region
transcript
express
induct
gener
fulllength
protein
prokuninaolsson
other
transcript
includ
produc
fulllength
protein
design
similar
transcript
produc
prematur
termin
protein
due
presenc
allel
result
frameshift
prokuninaolsson
other
reason
imposs
exclus
measur
mrna
express
transcript
produc
fulllength
howev
express
examin
via
assay
measur
ie
transcript
gener
fulllength
protein
transcript
similar
carri
allel
therefor
gener
nonfunct
protein
altern
possibl
use
allelespecif
assay
differenti
transcript
includ
allel
transcript
includ
allel
prokuninaolsson
other
use
former
approach
amanzada
other
analyz
mrna
express
region
liver
biopsi
specimen
patient
chronic
hepat
c
chronic
hepat
b
nonvir
liver
diseas
well
patient
without
liver
diseas
investig
found
region
transcript
present
liver
specimen
patient
hcv
infect
none
specimen
patient
liver
diseas
normal
liver
find
suggest
induct
mrna
liver
might
specif
hcv
infect
liver
biopsi
patient
hcv
infect
region
mrna
ie
could
detect
express
level
posit
correl
liver
hcv
rna
level
genotyp
author
interpret
find
suggest
level
hepat
hcv
rna
impact
level
transcript
irrespect
genotyp
consist
previou
studi
base
gwa
snp
amanzada
other
detect
higher
isg
express
carrier
allel
compar
without
allel
ie
genotyp
among
carrier
express
posit
correl
isg
express
amanzada
other
use
allelespecif
express
assay
konishi
other
analyz
region
mrna
express
level
liver
tissu
transplant
recipi
chronic
hepat
c
treat
pegyl
ifna
ribavirin
overal
report
region
mrna
express
recipi
among
recipi
carri
hepat
express
mrna
significantli
lower
patient
achiev
svr
compar
wherea
among
recipi
genotyp
treatment
respons
differ
mrna
level
investig
also
found
hepat
express
isg
higher
carrier
among
carrier
isg
level
posit
correl
express
level
consist
konishi
other
honda
other
found
hepat
express
isg
posit
correl
patient
chronic
hepat
c
investig
also
report
isg
express
liver
blood
posit
correl
among
patient
genotyp
ie
individu
gener
individu
carri
allel
may
express
low
level
protein
induc
low
persist
isg
express
liver
make
cell
refractori
stimul
ifna
note
earlier
individu
higher
basal
level
isg
express
despit
less
like
respond
effici
pegyl
ifna
ribavirin
therapi
recent
studi
examin
potenti
crossregulatori
effect
ifnl
ifna
respons
makowska
other
found
pretreat
mice
induc
state
refractori
secondari
challeng
ifna
vivo
francoisnewton
other
show
pretreat
phh
type
type
iii
ifn
vitro
suppress
subsequ
respons
ifna
studi
indic
pretreat
ifnl
inhibit
respons
secondari
challeng
ifna
may
relev
biolog
activ
anoth
recent
studi
suggest
mechan
action
could
involv
regul
express
measur
express
liver
biopsi
hcvinfect
patient
noninfect
control
duong
other
press
found
express
much
higher
biopsi
individu
chronic
hepat
c
among
hcvinfect
patient
express
significantli
higher
carri
allel
strong
ld
allel
patient
fail
respond
treatment
pegylatedifnaribavirin
compar
respond
phh
sampl
express
could
induc
ifna
express
significantli
stronger
sampl
carri
result
suggest
possibl
impair
hcv
clearanc
via
mechan
involv
upregul
recent
sheahan
other
appli
laser
captur
microdissect
cultur
phh
order
isol
transcript
profil
hcvinfect
cell
well
adjac
cell
uninfect
observ
transcript
respons
domin
innat
antivir
immun
signatur
greater
divers
infect
cell
noninfect
cell
cell
donor
carri
infect
higher
frequenc
antivir
program
infect
cell
donor
less
robust
infect
cell
donor
genotyp
result
suggest
may
impair
antivir
program
requir
effect
hcv
clearanc
sheahan
other
poor
correl
isg
express
liver
blood
among
patient
gener
could
link
observ
secret
appear
weak
gener
ifn
secret
protein
howev
found
primarili
intracellular
hypothes
could
due
weak
signal
peptid
prokuninaolsson
other
ham
other
confirm
secret
impair
conclud
due
weak
signal
peptid
experi
signal
peptid
exchang
secret
chimer
protein
consist
signal
peptid
remain
strong
secret
signal
peptid
chimera
remain
weak
moreov
ham
other
show
nlink
glycosyl
requir
effici
secret
contrast
glycosyl
requir
glycosyl
secret
therefor
impair
secret
might
due
ineffici
posttransl
glycosyl
also
possibl
intracellular
accumul
nonglycosyl
could
cytotox
result
cell
death
effici
secret
protein
could
conceiv
becom
extracellular
within
liver
result
cell
lysi
notabl
appear
case
least
one
type
ifn
ifnk
buontempo
other
fulllength
proteincod
transcript
initi
predict
human
primat
prokuninaolsson
other
howev
addit
genom
analysi
identifi
number
nonprim
mammal
although
mice
rat
tang
other
except
human
speci
avail
genom
sequenc
found
monomorph
allel
support
open
read
frame
tang
other
allel
underw
strong
neg
genet
select
replac
ancestr
allel
deriv
variant
nonafrican
popul
consist
earlier
report
base
thoma
other
allel
frequenc
vari
markedli
racial
ancestri
hapmap
popul
african
european
asian
carri
least
copi
variant
prokuninaolsson
other
allel
frequenc
consist
report
preced
discoveri
demonstr
chromosom
region
harbor
highli
select
human
ifn
region
manri
other
seem
unlik
select
driven
hcv
infect
hcv
rel
common
worldwid
shepard
other
howev
risk
factor
account
bulk
hcv
transmiss
blood
transfus
contamin
medic
inject
inject
drug
use
aros
primarili
twentieth
centuri
furthermor
hcv
usual
caus
slowli
progress
chronic
infect
unlik
markedli
impair
reproduct
signal
ifnl
receptor
complex
cell
indic
transfect
andor
treat
silenc
rna
cell
also
transfect
luciferas
report
construct
renilla
constitut
express
firefli
ifn
induc
adapt
ham
other
permiss
natur
publish
obrien
prokuninaolsson
donnelli
regard
infecti
agent
neither
analysi
base
snp
martin
other
publish
gwa
result
kamatani
other
provid
evid
might
impair
spontan
clearanc
hepat
b
viru
perhap
consist
recent
observ
note
express
hbvinfect
liver
amanzada
other
griffith
other
found
individu
ct
tt
genotyp
ie
like
carrier
frequent
episod
sever
herp
labiali
griffith
other
condit
result
reactiv
herp
simplex
viru
type
date
gwa
infecti
diseas
report
associ
variant
ifnl
region
discoveri
appear
explain
strong
genet
associ
observ
gwa
marker
within
ifnl
gene
cluster
hcv
clearanc
simultan
rais
number
question
concern
function
mechan
full
clinic
implic
novel
member
ifnl
famili
function
similar
differ
chromosom
neighbor
closest
rel
term
aminoacid
sequenc
may
provid
clue
regard
mechan
signal
ifnl
receptor
complex
activ
jakstat
pathway
induc
isg
exhibit
strong
antivir
activ
vitro
hand
differ
region
sequenc
weaker
secret
basi
genotyp
associ
impair
viral
clearanc
hcvinfect
individu
indic
earlier
strong
evid
signal
receptor
complex
despit
rel
low
sequenc
similar
region
bind
chain
also
evid
unlik
ifn
poorli
secret
protein
possibl
impair
hcv
clearanc
imped
receptor
bind
member
ifnl
famili
either
due
observ
differ
structur
secret
futur
studi
like
expand
understand
secret
signal
effici
recent
report
suggest
among
patient
chronic
hepat
c
carri
allel
lower
express
mrna
associ
higher
rate
svr
respons
pegyl
ifna
ribavirin
therapi
konishi
other
case
regulatori
genet
variant
clinic
factor
might
modul
express
could
impact
hcv
clearanc
individu
carri
measur
peripher
blood
might
clinic
use
biomark
howev
weak
secret
may
make
challeng
develop
assay
detect
blood
treatment
chronic
hepat
c
improv
rapidli
due
develop
direct
act
antivir
agent
daa
target
variou
aspect
hcv
life
cycl
daa
regimen
promis
markedli
increas
svr
rate
elimin
advers
effect
associ
ifna
treatment
phase
trial
patient
svr
respons
combin
faldaprevir
proteas
inhibitor
deleobuvir
polymeras
inhibitor
lower
patient
ct
tt
genotyp
zeuzem
other
trial
patient
treat
sofosbuvir
polymeras
inhibitor
along
ribavirin
allel
associ
slower
earli
viral
decay
meissner
other
result
suggest
genotyp
may
relev
ifnafre
daa
regimen
howev
treatment
suffici
durat
appear
genet
effect
overcom
almost
patient
may
respond
treatment
lawitz
other
howev
daa
regimen
promis
expens
lancet
treatment
cost
might
reduc
durat
therapi
could
person
basi
genotyp
factor
strong
select
pressur
allel
human
popul
could
result
infecti
agent
extinct
also
possibl
howev
play
import
role
contemporari
infecti
diseas
hcv
associ
infect
might
detect
studi
base
genotyp
gwa
also
seem
plausibl
genotyp
could
associ
impair
respons
ifnbas
treatment
clinic
condit
similar
associ
observ
treatment
chronic
hepat
c
ifna
use
regimen
treatment
chronic
hepat
b
howev
data
associ
genotyp
gwa
marker
link
respons
ifnabas
treatment
mix
jilg
chung
studi
treatment
multipl
sclerosi
ifnb
found
associ
genotyp
malhotra
other
final
notabl
detect
involv
complementari
use
differ
genom
approach
gwa
rnaseq
discoveri
rais
question
whether
genom
approach
might
lead
discoveri
import
immunolog
gene
